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The primary claim put forward by Dr. Mehta et al.
is that there is ‘‘reliable’’ evidence that autologous
stem cell transplantation is superior to conventional
chemotherapy. Any reasonable observer would con-
clude with the main findings of our systematic review
that there is a paucity of reliable data on the efficacy of
autologous stem cell transplantation in AL amyloid-
osis, and this is precisely the conclusion of our manu-
script [1].
Dr. Mehta’s main critique relate to omission of an
article by Dispenzieri et al. [2] from the systematic
review, and inclusion of this article would have some-
how changed the findings. Unfortunately, Mehta and
colleagues did not read the inclusion criteria of the
systematic review attentively. The study by Dispen-
zieri et al. [2] is a retrospective study as stated in the
first sentence of the Methods section. The inclusion
criteria of this systematic review [1] clearly mentions
inclusion of prospective studies only. Nevertheless,
for the sake of academic discussion, even if we in-
cluded retrospective case-controlled studies, we would
not know which of the studies published by Dispen-
zieri et al. are to be included. In 2001, Dispenzieri
et al. [3] published a study concluding that there is
no difference in outcomes between conventional
chemotherapy and autologous stem-cell transplanta-
tion. Using essentially the same population of amyloid
patients but different selection criteria for controls, in
2004, the authors reported that autologous stem cell
transplant might be superior [2]. Additionally, in
both the articles Dispenzieri et al. [2,3] called for ran-
domized-controlled trials to definitively address the
role of transplant in AL amyloidosis as the correct
methodologic approach to settle differences high-
lighted in variety of nonrandomized controlled trials.
Consequently, we are puzzled by this apparent rever-
sal of this stand, as expressed in the letter by Dr. Mehta
and colleagues.
Mehta et al. further state that, centers in France
[4] have limited experience in treating primary ALamyloidosis, and in his opinion that is the main
reason for high treatment-related mortality [4] while
claiming the superiority of the specialized centers
in treating primary systemic AL amyloidosis. The
proclaimed superiority of the specialized centers can
be equally explained by selection bias, as these centers
may treat selective group of patients (ie, good-risk
patients) as originally pointed out by Dispenizeri
et al. [3]. Therefore, if indeed, the specialized centers
have better outcomes with autologous transplanta-
tion in comparison with other centers, the onus of
proving such claim rests with physicians practicing
in such centers (eg, by undertaking an RCT to test
this hypothesis).
In another incidence of misstatement of facts, Dr.
Mehta and colleagues refer to a meta-analysis pub-
lished in the Journal of the National Cancer Institute as
‘‘erroneous’’ without referring to the author’s reply,
which highlights the lack of basic understanding of
the meta-analytic techniques [5]. Of note, the editorial
board of Journal of the National Cancer Institute exten-
sively reviewed the manuscript and reached a decision
that the meta-analysis was properly performed, and
thus we strongly believe represents important addition
to the existing knowledge on treatment of patients with
multiple myeloma [5,6].
In summary, critique of our article by Dr. Mehta
et al. [1] is compromised by poor understanding of
the hierarchy of evidence and how reliable data are
generated in clinical research. The key message our
systematic review highlights is the absence of good
methodological quality data on the efficacy of autol-
ogous transplantation in AL amyloidosis, and the ur-
gent need for adequately powered and good
methodological quality RCTs to conclusively address
the issue related to the efficacy of autologous trans-
plantation for AL amyloidosis. We cannot under-
stand how any researcher with even a minimum
understanding of the principles of evidence-based
medicine would conclude otherwise. We understand
that Mehta and colleagues do not agree with the re-
sults of our meta-analyses [1,6]. However, we hope
that in the future critiques will be based on true sci-
entific merit rather than distorted attacks using un-
reasonable language.REFERENCES
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of a Shortage of Bone
Marrow Filters
Many drugs and devices are essential to conduct
hematopoietic stem cell transplantation (HSCT).
The hematopoietic transplant community has been
influenced by numerous drug and device shortages
over the past several years in both Japan and other
countries. This problem has included critical drugs
for hematopoietic transplantations such as gancycrlo-
vir, dexamethasone, lenograstim, imipenam, and ce-
phepime. Recently, the discontinuation in the supply
of the anticancer drug thio-tepa was announced by
a pharmaceutical company in Japan; however, this pro-
cess and decision were not sufficiently disclosed by the
Ministry of Health, Labor, and Welfare (MHLW). As
a result, the hematopoietic transplant communities are
thus considered to urgently require the establishment
of effective management in the event of such future cri-
ses. Although information disclosure is a key to crisis
management, how to disclose bad news to patients re-
mains a difficult issue [1-3] because proactive informa-
tion disclosure may unnecessarily stir up the anxiety ofthe patients. The number of studies focusing on this
topic in the medical field is limited [4].
In December 2008, a termination of the supply of
the Bone Marrow Collection Kit (BMCK) made by
Baxter Limited (Tokyo, Japan) was identified in Japan.
This kit is used for filtering bone marrow(BM) aspirate
during BM transplantations (BMT) [5], and it is essen-
tial for the prevention of thrombosis associated with
the infusion of BM aspirate. As an alternative, the
Bone Marrow Correction System made by the venture
company BioAccess Inc. (Baltimore, MD) is available,
but this product had not been approved in Japan, al-
though it has been approved by the U.S. Food and
Drug Administration (FDA). In Japan, peripheral
blood stem cell transplantations (PBSCs) from unre-
lated donors are not approved, thus resulting in a reli-
ance on BM only, so there was a possibility that the
disruption in the supply of the BM filters would result
in a complete suspension of HSCT from unrelated do-
nors. Considering the stock quantity within Japan (ap-
proximately 500 units) held by Baxter at the end of
December, it was predicted that BMT would not be
available until mid-March 2009.
This problem was eventually resolved by the
prompt approval of the kit from BioAccess by
MHLW on February 26, 2009. However, during this
period, the problem of the disruption in the supply of
the BM filters was widely reported throughout the me-
dia in Japan, thereby generating great public interest.
This case shows the unfavorable impact onmedical
practice if the government does not proactively dis-
close information to society. The responses of
MHLW were slow, and no information was disclosed
